Skip to main content
NCBI home page
Japanese Journal of Cancer Research : Gann logoLink to Japanese Journal of Cancer Research : Gann
. 1999 Dec;90(12):1387–1395. doi: 10.1111/j.1349-7006.1999.tb00724.x

Evaluation of Antivascular and Antimitotic Effects of Tubulin Binding Agents in Solid Tumor Therapy

Yukio Nihei 1,✉, Manabu Suzuki 1, Akira Okano 1, Takashi Tsuji 1, Yukio Akiyama 1, Takashi Tsuruo 2, Sachiko Saito 3, Katsuyoshi Hori 3, Yasufumi Sato 3
PMCID: PMC5926039  PMID: 10665658

Abstract

Tubulin binding agents (TBAs) reduce tumor perfusion and inhibit mitosis of tumor cells in solid tumors, but it is not clear which effects contribute to the suppression of solid tumor growth. We evaluated the antivascular and antimitotic effects of several TBAs, combretastatin A‐4 (CS A‐4) phosphate, AC‐7700, a novel CS A‐4 derivative, colchicine, E7010, and vinblastine, on subcutaneous (s.c.) murine colon26 adenocarcinoma (c26). Tolerable doses of vinblastine and E7010 strongly inhibited tumor growth and induced mitotic arrest of tumor cells without affecting tumor perfusion. Colchicine had no effect on tumor growth and perfusion. When the injected dose was increased to the lethal range, however, these drugs markedly reduced tumor perfusion and caused necrosis of tumor tissue. Within the tolerable dose range, AC‐7700 both strongly suppressed tumor growth and reduced tumor perfusion, and CS A‐4 phosphate also exhibited a moderate antivascular effect. To evaluate the contribution of antivascular activity of TBAs to tumor growth suppression, excluding their direct cytotoxic effect on tumor cells, we established c26/acr, which is resistant to TBAs in vitro. Although E7010 showed a reduced suppressive effect on s.c. c26/acr tumor growth as compared with its effect on wild‐type c26, AC‐7700 remained potent against both cell lines. These results indicate that TBAs exert antivascular and antimitotic effects on solid tumors with marked differently effective dose ranges from agent to agent, and that the antivascular effect of TBAs inhibits solid tumor growth independently of the direct cytotoxic effect on tumor cells.

Keywords: Tubulin binding agent, Combretastatin, Tumor vessel, Antimitotic, Antivascular

Full Text

The Full Text of this article is available as a PDF (806.8 KB).

REFERENCES

  • 1. ) Baguley , B. C. , Holdaway , K. M. , Thomsen , L. L. , Zhuang , L. and Zwi , L. J.Inhibition of growth of colon38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism . Eur. J. Cancer , 27 , 482 – 487 ( 1991. ). [DOI] [PubMed] [Google Scholar]
  • 2. ) Hill , S. A. , Lonergan , S. J. , Denekamp , J. and Chaplin , D. J.Vinca alkaloids: anti‐vascular effects in a murine tumor . Eur. J. Cancer , 29A , 1320 , 1324 – 1993. . [DOI] [PubMed] [Google Scholar]
  • 3. ) Chaplin , D. J. , Pettit , G. R. , Parkins , C. S. and Hill , S. A.Antivascular approaches to solid tumor therapy: evaluation of tubulin binding agents . Br. J. Cancer , 74 ( Suppl. XXVII ), S86 – S88 ( 1996. ). [PMC free article] [PubMed] [Google Scholar]
  • 4. ) Hill , S. A. , Sampson , L. E. and Chaplin , D. J.Anti‐vascular approaches to solid tumor therapy: evaluation of vinblastine and flavone acetic acid . Int. J. Cancer , 63 , 119 – 123 ( 1995. ). [DOI] [PubMed] [Google Scholar]
  • 5. ) Pettit , G. R. , Singh , S. B. , Hamel , E. , Lin , C. M. , Alberts , D. S. and Garcia‐Kendall , D.Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A‐4 . Experientia , 45 , 209 – 211 ( 1989. ). [DOI] [PubMed] [Google Scholar]
  • 6. ) Cushman , M. , Nagarathnam , D. , Gopal , D. , He , H.‐M. , Lin , C. M. and Hamel , E.Synthesis and evaluation of analogues of (Z)‐1‐(4‐methoxyphenyl)‐2‐(3,4,5‐trimethoxy‐phenyl)ethene as potential cytotoxic and antimitotic agents . J. Med. Chem. , 35 , 2293 – 2306 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 7. ) Woods , J. A. , Hadfield , J. A. , Pettit , G. R. , Fox , B. W. and McGown , A. T.The interaction with tubulin of a series of stilbenes based on combretastatin A‐4 . Br. J. Cancer , 71 , 705 – 711 ( 1995. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. ) Dark , G. G. , Hill , S. A. , Prise , V. E. , Tozer , G. M. , Pettit , G. R. and Chaplin , D. J.Combretastatin A‐4, an agent that displays potent and selective toxicity toward tumor vasculature . Cancer Res. , 10 , 1829 – 1834 ( 1997. ). [PubMed] [Google Scholar]
  • 9. ) Dorr , R. T. , Dvorakova , K. , Snead , K. , Alberts , D. S. , Salmon , S. E. and Pettit , G. R.Antitumor activity of combretastatin‐A4 phosphate, a natural product tubulin inhibitor . Invest. New Drugs , 14 , 131 – 137 ( 1996. ). [DOI] [PubMed] [Google Scholar]
  • 10. ) Ohsumi , K. , Nakagawa , R. , Fukuda , Y. , Hatanaka , T. , Morinaga , Y. , Nihei , Y. , Ohishi , K. , Suga , Y. , Akiyama , Y. and Tsuji , T.Novel combretastatin analogues effective against murine solid tumors; design and structure‐activity relationships . J. Med. Chem. , 41 , 3022 – 3032 ( 1998. ). [DOI] [PubMed] [Google Scholar]
  • 11. ) Nihei , Y. , Suga , Y. , Morinaga , Y. , Ohishi , K. , Okano , A. , Ohsumi , K. , Hatanaka , T. , Nakagawa , R. , Tsuji , T. , Akiyama , Y. , Saito , S. , Hori , K. , Sato , Y. and Tsuruo , T.A novel combretastatin A‐4 derivative, AC‐7700, shows marked antitumor activity against advanced solid tumors and orthotopically transplanted tumors . Jpn. J. Cancer Res. , 90 , 1016 – 1025 ( 1999. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. ) Koyanagi , N. , Nagasu , T. , Fujita , F. , Watanabe , T. , Tsukahara , K. , Funahashi , Y. , Fujita , M. , Taguchi , T. , Yoshino , H. and Kitoh , K.In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors . Cancer Res. , 54 , 1702 – 1706 ( 1994. ). [PubMed] [Google Scholar]
  • 13. ) Bibby , M. C. , Double , J. A. , Loadman , P. M. and Duke , C. V.Reduction of tumor blood flow by flavone acetic acid: a possible component of therapy . J. Natl. Cancer Inst. , 81 , 216 – 220 ( 1989. ). [DOI] [PubMed] [Google Scholar]
  • 14. ) Dvorak , H. F. , Nagy , J. A. , Dvorak , J. T. and Dvorak , A. M.Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules . Am. J. Pathol. , 133 , 95 – 109 ( 1988. ). [PMC free article] [PubMed] [Google Scholar]
  • 15. ) Hori , K. , Saito , S. , Nihei , Y. , Suzuki , M. and Sato , Y.Antitumor effects due to irreversible stoppage of tumor tissue blood flow: evaluation of a novel combrestatin A‐4 derivative, AC7700 . Jpn. J. Cancer Res. , 90 , 1026 – 1038 ( 1999. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. ) Andrade , S. P. , Hart , I. R. and Piper , P. J.Inhibitors of nitric oxide synthase selectively reduce flow in tumor‐associated neovasculature . Br. J. Pharmacol. , 107 , 1092 – 1095 ( 1992. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. ) Tozer , G. M. , Prise , V. E. and Chaplin , D. J.Inhibition of nitric oxide synthase induces a selective reduction in tumor blood flow that is reversible with L‐arginine . Cancer Res. , 57 , 948 – 955 ( 1997. ). [PubMed] [Google Scholar]
  • 18. ) Peters , C. E. and Chaplin , D. J.Blood flow modification in the SCC2 tumor: effects of 5‐hydroxytryptamine, hydralazine, and propranolol . Int. J. Radiat. Oncol. Biol. Phys. , 22 , 463 – 465 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 19. ) Dewhirst , M. W. , Madwed , D. , Meyer , R. E. , Ong , E. T. , Klitzman , B. , Rosner , G. L. and Dodge , R.Reduction in tumor blood flow in skin flap tumor after hydralazine is not due to a vascular steal phenomenon . Radiat. Oncol. Invest. , 1 , 270 – 278 ( 1994. ). [Google Scholar]
  • 20. ) Jain , R. K.Transport of molecules in the tumor interstitium: a review . Cancer Res. , 47 , 3039 – 3051 ( 1987. ). [PubMed] [Google Scholar]
  • 21. ) Boucher , Y. and Jain , R. K.Micro vascular pressure is the principal driving force for interstitial hypertension in solid tumors: implication for vascular collapse . Cancer Res. , 52 , 5110 – 5114 ( 1992. ). [PubMed] [Google Scholar]
  • 22. ) Watts , M. , Woodcock , M. , Arnold , S. and Chaplin , D. J.Effects of novel and conventional anti‐cancer agents on human endothelial permeability: influence of tumor secreted factors . Anticancer Res. , 17 , 71 – 76 ( 1997. ). [PubMed] [Google Scholar]
  • 23. ) McGown , A. T. and Fox , B. W.Structural and biochemical comparison of the anti‐mitotic agents colchicine, combretastatin A4, and amphethinile . Anticancer Drug Des. , 3 , 249 – 254 ( 1989. ). [PubMed] [Google Scholar]
  • 24. ) Yoshino , H. , Ueda , N. , Niijima , J. , Sugumi , H. , Kotake , Y. , Koyanagi , N. , Yoshimatsu , K. , Asada , M. , Watanabe , T. , Nagasu , T. , Tsukahara , K. , Iijima , A. and Kitoh , K.Novel sulfonamides as potential, systemically active antitumor agents . J. Med. Chem. , 35 , 2496 – 2497 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 25. ) Yoshimatsu , K. , Yamaguchi , A. , Yoshino , H. , Koyanagi , N. and Kitoh , K.Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin . Cancer Res. , 57 , 3208 – 3213 ( 1997. ). [PubMed] [Google Scholar]

Articles from Japanese Journal of Cancer Research : Gann are provided here courtesy of Wiley

RESOURCES